Innate Pharma SA IPHA 深 沪
等待开盘 10-01 09:30:00 美东时间
1.63
+0.030
+1.88%
华盛通- 最 高1.78
- 今 开1.61
- 成交量 3.78万股
- 最 低 1.61
- 昨 收 1.60
- 总市值 1.82亿
- 52周最高 2.71
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 1.17
- 委 比 -7.28%
- 总股本 1.12亿
- 历史最高 11.95
- 量 比 1.29
- 振 幅 10.63%
- 历史最低 1.17
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target
BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.
09-17 23:51
Innate Pharma H1 2026 Earnings Call Transcript
Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. Access the full call at https://event...
09-17 20:27
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10 million. Companies Reporting After The Bell • Upexi (NASDAQ:UPXI) is estimated to r...
09-17 19:11
Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $6.583 million wh...
09-17 13:12
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股牛股 | BWNM飙升55%，获私募巨头溢价近6成收购；获华尔街投行齐声看多，STDN劲升35%；医药股ABCL大涨34%
BWNM飙升55%，获私募巨头溢价近6成收购；STDN劲升35%，机构称其在三结构各向同性核燃料市场中；医药股ABCL升超34%，潮热治疗药物中期试验效果积极>>
08-11 15:48
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (NASDAQ:IPHA) on Monday forged a strategic alliance to launch a critical Phase 3 clinical trial targeting a rare form of skin cancer. The collaboration primarily focuses on enabling the TELLOMAK-3 study, a crucial milestone intended to fast-tra...
08-10 22:03
